首页> 外文期刊>Epilepsy research >Noninvasive screening for preclinical atherosclerosis in children on phenytoin or carbamazepine monotherapy: A cross sectional study
【24h】

Noninvasive screening for preclinical atherosclerosis in children on phenytoin or carbamazepine monotherapy: A cross sectional study

机译:苯妥英钠或卡马西平单药治疗儿童临床前动脉粥样硬化的非侵入性筛查:一项横断面研究

获取原文
获取原文并翻译 | 示例
           

摘要

Purpose: This study was carried out to compare the carotid Intimal Media Thickness (IMT), and endothelial function using brachial flow mediated dilatation (FMD), in Epileptic children (6-12 years) on phenytoin (PHT) or carbamazepine (CBZ) monotherapy for ≥18 months with a control group of children. Methods: In this cross-sectional study 30 children (aged 6-12 years) on PHT monotherapy and 28 children on CBZ monotherapy were compared with an equal number of apparently healthy age and sex matched children unexposed to antiepileptics. Fasting lipids, sugar, Hs-CRP levels and ultrasonographic assessment of carotid IMT and endothelial function using brachial FMD were conducted. Results: The age (years) of the children in the CBZ group (9.1. ±. 2), PHT group (9.4. ±. 2) and the controls (9.3. ±. 2) was comparable. The duration of CBZ therapy was 30.8. ±. 13.2 months and that of PHT therapy was 29.5. ±. 13.6 months. The mean dose of CBZ was 18.18. ±. 8.5. mg/kg and that of PHT was 5.5. ±. 2.3. mg/kg body weight. The time since last seizure was 15.6. ±. 8.4 months in the CBZ group and 17.3. ±. 10.4 months in the PHT group. The fasting blood sugar was below 110. mg/dl in all children.The height, weight, waist and hip measurements, waist hip ratio and blood pressures were similar in the groups. The total cholesterol levels (161.7. ±. 24.8 vs 140.2. ±. 20.8. mg/dl, p= 0.001), HDL (53.8. ±. 10.5 vs 47.1. ±. 8.8. mg/dl, p= 0.017) and LDL (85. ±. 21.1 vs 70.9. ±. 19.4. mg/dl, p= 0.01) were significantly higher in the CBZ group compared to the control group. The HDL levels (54.6. ±. 9.4 vs 45.8. ±. 7.7. mg/dl, p<. 0.0001) were significantly higher in the PHT group compared to the control group. The right carotid (0.374. ±. 0.04 vs 0.339. ±. 0.05. mm, p=0.012), left carotid (0.382. ±. 0.05 vs 0.351. ±. 0.05. mm, p=0.044) and the overall average carotid intima media thickness (0.378. ±.048 vs 0.345. ±. 052. mm, p= 0.018) of the children on CBZ was significantly higher than the carotid IMT in control group children. The right carotid (0.370. ±. 0.04 vs 0.342. ±. 0.05. mm, p= 0.032) and the overall average carotid IMT (0.374. ±. 0.04 vs 0.348. ±. 0.05. mm, p= 0.035) of the children on PHT was significantly higher than the carotid IMT in controls. The FMD were comparable in the children on CBZ or PHT and the control group. Conclusions: The results are preliminary but could signal the increased vulnerability of epileptic children on long term antiepileptics to have subclinical atherosclerosis.
机译:目的:本研究旨在比较苯妥英钠(PHT)或卡马西平(CBZ)单药治疗的癫痫儿童(6-12岁)的颈动脉内膜中层厚度(IMT)和使用肱动脉血流介导的扩张(FMD)的内皮功能对照组儿童≥18个月。方法:在这项横断面研究中,将30例接受PHT单药治疗的儿童(6-12岁)和28例采用CBZ单药治疗的儿童与未暴露于抗癫痫药的相同年龄,性别相同的健康儿童进行了比较。进行空腹血脂,糖分,Hs-CRP水平以及使用肱FMD进行超声检查评估颈动脉IMT和内皮功能。结果:CBZ组(9.1。±。2),PHT组(9.4。±。2)和对照组(9.3。±。2)的儿童年龄(岁)相当。 CBZ治疗的持续时间为30.8。 ±。 13.2个月,PHT疗法为29.5个月。 ±。 13.6个月。 CBZ的平均剂量为18.18。 ±。 8.5。 mg / kg和PHT为5.5。 ±。 2.3。 mg / kg体重。自上次癫痫发作以来的时间为15.6。 ±。 CBZ组为8.4个月,17.3为。 ±。 PHT组为10.4个月。所有儿童的空腹血糖均低于110. mg / dl。各组的身高,体重,腰围和臀围测量值,腰臀比和血压均相似。总胆固醇水平(161.7。±.24.8 vs 140.2。±。20.8。mg / dl,p = 0.001),HDL(53.8。±。10.5 vs 47.1。±。8.8。mg / dl,p = 0.017)和LDL与对照组相比,CBZ组(85.±。21.1 vs 70.9。±。19.4。mg / dl,p = 0.01)显着更高。与对照组相比,PHT组的HDL水平(54.6。±9.4 vs 45.8。±。7.7。mg / dl,p <.0.0001)显着更高。右颈动脉(0.374。±.0.04 vs 0.339。±.0.05.mm,p = 0.012),左颈动脉(0.382。±。0.05 vs 0.351。±.0.05.mm,p = 0.044)和颈动脉内膜总平均CBZ患儿的中层厚度(0.378。±.048 vs 0.345。±。052. mm,p = 0.018)显着高于对照组儿童的颈动脉IMT。儿童的右颈动脉(0.370。±.0.04 vs 0.342。±.0.05.mm,p = 0.032)和总平均颈动脉IMT(0.374。±.0.04 vs 0.348。±.0.05.mm,p = 0.035)在对照中,PHT的作用显着高于颈动脉IMT。在使用CBZ或PHT的儿童与对照组中,FMD相当。结论:该结果是初步的,但可能预示着长期服用抗癫痫药的癫痫儿童易患亚临床动脉粥样硬化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号